We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Non-inferiority Trial on Monoclonal Antibodies in COVID-19 (MANTICO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05205759
Recruitment Status : Terminated (Stop for futility after the onset of the omicron wave)
First Posted : January 25, 2022
Last Update Posted : July 26, 2022
Agenzia Italiana del Farmaco
Azienda Sanitaria-Universitaria Integrata di Udine
Information provided by (Responsible Party):
Evelina Tacconelli, Azienda Ospedaliera Universitaria Integrata Verona

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : February 5, 2022
Actual Study Completion Date : April 5, 2022
U.S. Department of Health and Human Services Food and Drug Administration. Assessing COVID19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment. Available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs. Accessed 30 March 2022.